Irvine Pharmaceutical Services competitors

Cameron Reid is a Board Member at CHEMINOR DRUGS LIMITED and Chief Executive Officer at Interpharm Holdings Inc. He has worked as President at DR. REDDY'S LABORATORIES and Board Member at Interpharm Holdings Inc. Cameron works or has worked as Executive Vice President at Roussel NV. He studied at UCalgary and INSEAD.

David Seltzer is a Chairman/Pres/CEO/Treasurer at HI TECH PHARMACAL CO INC, Board Member at NovelStem International Corp, and Owner at Leading Pharma. He has experience at Bergen Brunswig Corp and AMERISOURCEBERGEN CORP and has worked as Exec VP:Admin/Treasurer/Secy at HI TECH PHARMACAL CO INC, Treasurer/Secretary at HI TECH PHARMACAL CO INC, and VP:Admin/COO/Treasurer/Secy at HI TECH PHARMACAL CO INC. David attended Queens University of Charlotte.

Ian Lennox is a CEO/Chairman at Olon Ricerca Bioscience LLC. He attended HBSc and MBA.

Accomplished scientific leader with more than 30 years of pharmaceutical experience. From discovery through research & development, analytical (method development, validation, etc.) and quality control drug discovery and management experience in top-tier multinational pharmaceutical organizations. A global, strategic thinker, with demonstrated ability to deliver pre-clinical and clinical candidates, within stringent timelines. Acknowledged as a creative leader focused on advancing projects with experience in multiple therapeutic areas. Expert in optimizing the drug discovery process through optimal resource allocation, process improvements and using scientific acumen to resolve complex project related issues. Recognized ability to lead, recruit, energize, mentor, reward and retain talent. Specialties: Executive Management / Pharmaceuticals / Drug Discovery & Development / Pre-Clinical & Clinical Development / Product Development / Start-Up Experience/ Analytical chemistry / Preformulation / Marine natural products (microbial) / Marine biology /Chemistry / Pharmaceuticals

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to several successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry-leading position in the marketplace. After earning his doctorate in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide.